Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis
Intercell AG announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens Serum Institut formulated with Intercells adjuvant IC31®, will be further developed in a partnership between SSI and Sanofi Pasteur.
SSI and Intercell will continue their collaboration in the field of Tuberculosis research and vaccine development with Intercell's proprietary adjuvant IC31®, and by the involvement of Sanofi Pasteur extend the activities into more advanced phases aiming to make a new TB vaccine widely available in shortest possible time.
The collaboration with Aeras Global TB Vaccine Foundation in the TB vaccine field will continue and together the parties represent the extensive range of technology and expertise necessary to solve this complex global health problem.
We are very happy that Sanofi Pasteur is now contributing all its outstanding vaccine expertise to this very promising tuberculosis vaccine program comments Intercells Chief Executive Officer Gerd Zettlmeissl. The preclinical and the Phase I clinical studies performed so far have impressively proven that our novel adjuvant IC31® will play an important role in this combined vaccine approach.
Financial details are not disclosed.
Other news from the department science
